Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma

A disintegrin and metalloprotease 10 (ADAM10) is a typical member of the ADAMs family, which has been reported to be upregulated in various types of cancers and contribute to cancer progression and metastasis. However, little is known about the role of ADAM10 in nasopharyngeal carcinoma (NPC). The p...

Full description

Bibliographic Details
Main Authors:	You, Bo, Shan, Ying, Shi, Si, Li, Xingyu, You, Yiwen
Format:	Online
Language:	English
Published:	John Wiley and Sons Inc. 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714676/

id	pubmed-4714676
recordtype	oai_dc
spelling	pubmed-47146762016-01-22 Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma You, Bo Shan, Ying Shi, Si Li, Xingyu You, Yiwen Original Articles A disintegrin and metalloprotease 10 (ADAM10) is a typical member of the ADAMs family, which has been reported to be upregulated in various types of cancers and contribute to cancer progression and metastasis. However, little is known about the role of ADAM10 in nasopharyngeal carcinoma (NPC). The purpose of this study is to explore ADAM10 expression status and its biological functions in NPC. We first examined the expression of ADAM10 in NPC tissues and cell lines by immunohistochemistry, Western blotting, PCR, and immunofluorescence analysis. We observed that ADAM10 was significantly elevated in NPC and its expression level was correlated with T classification (P = 0.044), distant metastasis (P = 0.016), TNM clinical stage (P = 0.013), and proliferation marker Ki‐67 expression (P = 0.001). Patients with NPC with high expression of ADAM10 had shorter overall survival rates. In addition, knockdown of ADAM10 by RNAi was found to inhibit the CNE‐2 cell proliferation and migration. Our findings hinted that overexpression of ADAM10 promotes the progression and migration of NPC, which makes it a potential therapeutic target for the treatment of tumor metastases in NPC. John Wiley and Sons Inc. 2015-10-14 2015-11 /pmc/articles/PMC4714676/ /pubmed/26310711 http://dx.doi.org/10.1111/cas.12800 Text en © 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	You, Bo Shan, Ying Shi, Si Li, Xingyu You, Yiwen
spellingShingle	You, Bo Shan, Ying Shi, Si Li, Xingyu You, Yiwen Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma
author_facet	You, Bo Shan, Ying Shi, Si Li, Xingyu You, Yiwen
author_sort	You, Bo
title	Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma
title_short	Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma
title_full	Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma
title_fullStr	Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma
title_full_unstemmed	Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma
title_sort	effects of adam10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma
description	A disintegrin and metalloprotease 10 (ADAM10) is a typical member of the ADAMs family, which has been reported to be upregulated in various types of cancers and contribute to cancer progression and metastasis. However, little is known about the role of ADAM10 in nasopharyngeal carcinoma (NPC). The purpose of this study is to explore ADAM10 expression status and its biological functions in NPC. We first examined the expression of ADAM10 in NPC tissues and cell lines by immunohistochemistry, Western blotting, PCR, and immunofluorescence analysis. We observed that ADAM10 was significantly elevated in NPC and its expression level was correlated with T classification (P = 0.044), distant metastasis (P = 0.016), TNM clinical stage (P = 0.013), and proliferation marker Ki‐67 expression (P = 0.001). Patients with NPC with high expression of ADAM10 had shorter overall survival rates. In addition, knockdown of ADAM10 by RNAi was found to inhibit the CNE‐2 cell proliferation and migration. Our findings hinted that overexpression of ADAM10 promotes the progression and migration of NPC, which makes it a potential therapeutic target for the treatment of tumor metastases in NPC.
publisher	John Wiley and Sons Inc.
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714676/
_version_	1613524633543245824

Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma

Similar Items